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ABSTRACT
The DNMT3A R882H mutation is frequently observed
in acute myeloid leukemia (AML). It is located in the
subunit and DNA binding interface of DNMT3A and
has been reported to cause a reduction in activ-
ity and dominant negative effects. We investigated
the mechanistic consequences of the R882H mu-
tation on DNMT3A showing a roughly 40% reduc-
tion in overall DNA methylation activity. Biochemical
assays demonstrated that R882H does not change
DNA binding affinity, protein stability or subnuclear
distribution of DNMT3A. Strikingly, DNA methylation
experiments revealed pronounced changes in the
flanking sequence preference of the DNMT3A-R882H
mutant. Based on these results, different DNA sub-
strates with selected flanking sequences were de-
signed to be favored or disfavored by R882H. Kinetic
analyses showed that the R882H favored substrate
was methylated by R882H with 45% increased rate
when compared with wildtype DNMT3A, while methy-
lation of the disfavored substrate was reduced 7-fold.
Our data expand the model of the potential carcino-
genic effect of the R882H mutation by showing CpG
site specific activity changes. This result suggests
that R882 is involved in the indirect readout of flank-
ing sequence preferences of DNMT3A and it may ex-
plain the particular enrichment of the R882H mutation
in cancer patients by revealing mutation specific ef-
fects.
INTRODUCTION
Cancers acquire somatic DNA mutations as well as epi-
genetic changes, which ultimately confer a growth advan-
tage to the affected cells (1–5). These two mechanisms of
carcinogenesis are directly connected in cases when muta-
tions occur in epigenetic enzymes like DNA and histone
methyltransferases and demethylases. Such mutations have
recently been observed in many human cancers (6–9). In
2010, first studies have reported particularly high frequen-
cies of missense mutations in the DNMT3A DNA methyl-
transferase in acute myeloid leukemia (AML) (10,11). They
were confirmed by several other follow up reports (reviews:
(9,12)) showing that up to 25% of all AML patients con-
tain DNMT3A mutations, and even 37% of all AML pa-
tients with a normal karyotype (10). Recurrent DNMT3A
mutations have also been identified at lower frequencies in
other cancers, including myelodysplastic syndrome (MDS)
and T-cell lymphomas (reviews: (9,12)). DNMT3A muta-
tions in AML usually occur heterozygously in only one al-
lele that is accompanied by an intact wildtype allele and
they show a strong enrichment of missense mutations (73%
of all mutations, Supplementary Figure S1A). In partic-
ular arginine 882 in the catalytic C-terminal domain of
DNMT3A is often mutated (65% of all missense mutations
in DNMT3A, Supplementary Figure S1B), it is most of-
ten exchanged by histidine (66% of all R882 mutations).
DNMT3Amutations are a negative prognostic marker cor-
related with a reduced time to treatment failure, shorter du-
ration of complete remission and decreased disease-free sur-
vival in cytogenetically normal AML (12,13). Recent stud-
ies demonstrated that DNMT3A mutations occur early in
pre-leukemic cells and they act as driver mutations of the
carcinogenic process (12–15).
The structure of the C-terminal domain of DNMT3A
(DNMT3AC) in complex with the C-terminal domain of
its stimulator DNMT3L forms a linear heterotetramer con-
sisting of two DNMT3L subunits (at the edges of the
tetramer) and two DNMT3A molecules (in the center) (16)
(Supplementary Figure S1C). The DNMT3A/3L interface
is called FF interface and also used for multimerization
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of DNMT3A (17,18). The inner DNMT3A/3A interface,
called RD interface, also forms the DNA binding site of
the DNMT3A complex (16,17). This is a polar interface
mediating a reversible oligomerization of DNMT3A FF-
interface dimers into a mixture of dimers, tetramers and
higher aggregates depending on the buffer conditions and
enzyme concentrations (17–19). The R882Hmutation is lo-
cated in the RD interface implying potential effects on mul-
timerization of DNMT3A and its DNA interaction (Sup-
plementary Figure S1C).
Despite intensive work, the molecular and biochemical
mechanism of leukemia initiation through the DNMT3A-
R882H mutation has not yet been fully clarified (13). The
high prevalence of this particular missense mutation, to-
gether with the low frequency of non-sense and frameshift
mutations indicates that it must have a specific mechanistic
effect at the molecular level. Different studies have deter-
mined the catalytic activity of the purified R882H mutant
and often observed 50–70% residual activity of the mutant
enzyme (11,20,21). Later, studies reported that the R882H
mutation exhibits a dominant negative effect in cells and
in vitro. Kim et al. showed that the exogenously expressed
murine R878H mutant (corresponding to human R882H)
interacts with the wildtype enzyme, but it was less effi-
ciently methylating major satellite repeats in mouse ES cells
(22). Russler-Germain et al. described that mixed enzyme
preparations obtained after co-expression of wildtype and
R882H in mammalian cells only showed a weak residual
activity, suggesting that the complex formation of wildtype
and R882H subunits inactivates the wildtype subunits in a
dominant negative manner (23). However, it remains un-
clear, why the heterozygous R882H mutation is so strongly
enriched and why it is not accompanied by a larger number
of cases showing other forms of loss-of-function mutations
like frameshifts or non-sensemutations in both alleles of the
Dnmt3a gene.
MATERIALS AND METHODS
Site-directed mutagenesis, protein expression and purifica-
tion
Mutagenesis was performed using the megaprimer site-
directed mutagenesis method (24) and confirmed by re-
striction marker analysis and DNA sequencing. The C-
terminal domain of humanDNMT3A (Q9Y6K1.4) (amino
acids 612–912) and its R882H mutant were cloned into
pET28+ (Novagen) creating anN-terminal His6-tag fusion.
His-tagged DNMT3AC and R882H were overexpressed in
BL21 (DE3)Codon+RILEscherichia coli cells (Stratagene)
and purified as described (25). Briefly, cells were grown in
TB medium until an A600nm of 0.6 was reached and pro-
tein expression was induced for 12 h at 20◦C by addition of
0.5 mM isopropyl-1-thio--D-galactopyranoside. The pro-
teins were purified at high micromolar concentrations using
Ni–NTA agarose and stored in 20 mMHEPES pH 7.5, 200
mM KCl, 0.2 mM DTT, 1 mM EDTA and 10% glycerol at
–80◦C. The concentrations of the proteins were determined
by UV spectrophotometry and confirmed by densitometric
analysis of Coomassie stained SDS-polyacrylamide gels.
Methyltransferase activity assay
The methyltransferase activity of DNMT3AC and the
R882H mutant was measured using 100 nM of a biotiny-
lated 509mer containing 58 CpG sites using the follow-
ing primers (Bt-AGA TTA GGG AAG GGG GTG TG
and AAG ATC CTT TCA AGG CCT CAG) as described
(25) (Supplementary Figure S2). To study the flanking se-
quence effect on the activity of DNMT3AC and R882H,
DNA methylation kinetics were measured using 1 M bi-
otinylated double stranded 30-mer oligonucleotides con-
taining a single CpG site, which were designed to be pre-
ferred or disfavored byR882H. In both substrates, the lower
DNA strand was biotinylated. The correct annealing of the
individual strands was confirmed on polyacrylamide gels
stainedwith gel red. To study the specificmethylation of one
CpG site in oneDNA strand, the oligonucleotide substrates
were used in hemimethylated form and with the central
CpG site in fullymethylated form (26). The fullymethylated
substrate could only be methylated at non-CpG sites in the
flanking regions. The rate of methylation of the upper DNA
strand at the target site was calculated by subtracting the ac-
tivity observed with the fully methylated substrate from the
activity observed with the hemimethylated substrate. Con-
sideration of the fully methylated control was necessary to
determine methylation rates at single CpG sites, because
DNMT3A shows a high activity at some non-CpG sites
(27), which otherwise would obscure the results.
With both substrates, DNA methylation was measured
by the incorporation of tritiated methyl groups from ra-
dioactively labeledAdoMet (Perkin Elmer) into the biotiny-
lated substrate using an avidin–biotin methylation plate as-
say (28). The methylation reactions were carried out in
methylation buffer (20 mM HEPES pH 7.5, 1 mM EDTA,
50 mM KCl, 0.05 mg/ml bovine serum albumin) at 37◦C
using 2 M DNMT3AC wildtype or mutant enzyme. The
reactions were started by adding 0.76 M AdoMet. The
initial slope of the enzymatic reaction was determined by
linear regression. To determine the thermal stability of
DNMT3AC and R882H, one sample mix was prepared
for each enzyme without DNA and split into two reaction
tubes. In one tube the DNA methylation reaction was im-
mediately started by addingDNAandAdoMet. The second
tube was kept at 22◦C or 37◦C for 30 min before starting the
methylation reaction.
In vitro bisulfite DNA methylation studies were carried
out using the 509mer DNA fragment and primers specific
for the converted DNA (GTG GGA TTT GGT TTT GTT
TTG TAT TTT and GAA TAT TAC TAC TAC CCT CCT
CCT TCT CAA TTT AAC) covering 56 CpG sites as de-
scribed (25,29) and analyzed with BISMA (30,31).
DNA binding analysis of DNMT3A
DNA binding was investigated by fluorescence depolariza-
tion using a Cy5-labeled 29mer oligonucleotide substrate
(5′-ACT TGC AAC GGT CCT AAC CGT CAC CTC TT-
3′) as described (25,32). The binding reactions were carried
out in binding buffer containing 20 mM HEPES pH 7.5,
100 mM KCl, 1 mM EDTA, 2 nM of Cy5-labeled DNA
and increasing concentration of protein after incubation at
room temperature for 5 min. Each data point was measured
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Figure 1. Catalytic activity and characterization of the R882H mutant. (A) DNA methylation activity of DNMT3A catalytic domain and the R882H
mutant using a 509mer DNA substrate. The bars represent the average of 5 experiments, error bars indicate the standard error of the mean. See also
Supplementary Figure S3. (B) Protein stability of wildtype DNMT3AC and R882H analyzed by the loss of enzymatic activity during a pre-incubation of
the protein for 30 min at different temperatures. Error bars indicate the SEM based on 2 independent experiments. (C) CD spectra of wildtype DNMT3AC
and R882H. The similar shape of the spectra indicates comparable folding of both proteins. (D) Thermal stability of DNMT3AC and R882H analyzed by
CD melting at protein concentrations of 22 M for DNMT3AC and 8 M for R882H. Quantitative analysis revealed identical melting temperatures of
49.3 ± 0.4◦C and 49.5 ± 0.6◦C for DNMT3AC and R882H. (E) DNA binding titration of the R882H mutant to a 29mer DNA substrate. The data points
show the average of two experiments and the standard error. The line shows a fit of the data with a KD of 209 nM. (F) Heterochromatic localization of
EYFP fused murine DNMT3A containing the R878H mutation (corresponding to R882H in human DNMT3A).
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in triplicate and the average anisotropy values were taken
for the analysis. Data were least squares fitted using an equi-
librium binding model to determine the dissociation con-
stant (KD) of DNA binding. Error analysis was based on
the separate analysis of experimental repeats. DNA bind-
ing of wildtype DNMT3AC and R882H was measured side
by side, the results obtainedwith wildtypeDNMT3AChave
already been published (25).
Subnuclear localization of DNMT3A
The subnuclear localization of DNMT3A was analyzed
by fluorescence microscopy as described using EYFP fu-
sions of murine DNMT3A (18,32). To study the localiza-
tion of R882H, the R878H mutation was introduced into
the murine DNMT3A (which corresponds to R882H in the
human protein).
Circular dichroism (CD) spectroscopy
Folding of purified proteins was analyzed by CD spec-
troscopy. CD measurements were performed using a J-815
circular dichroism spectrophotometer (JASCO Corpora-
tion, Tokyo, Japan) in 200mMKCl, 20mMHEPES pH7.5,
10% glycerol using 10 Mpurified His-tagged DNMT3AC
or R882H. The spectra were collected at 21◦C using a 0.1
mm cuvette in a wavelength range between 195 and 240 nm.
For each sample, at least 30 scans were collected and aver-
aged. CD melting experiments were performed in dialysis
buffer using enzyme concentrations as indicated. The CD
signal was measured at a wavelength of 222 nm in a 0.1 mm
cuvette in the temperature range from 20 to 70◦C applying a
temperature increase of 2◦C/min. The melting temperature
was determined as described (33).
RESULTS
The catalytic domain of DNMT3A (DNMT3AC) is enzy-
matically active (34) indicating that it is a suitable model
system to study the effects of DNMT3A mutations on en-
zymatic properties and the RD domain interface (16). To
search for the enzymatic effects of DNMT3A R882H mu-
tations, we have prepared the R882H mutant in the context
of DNMT3AC and purified the proteins after recombinant
expression in E. coli (Supplementary Figure S1D).
Characterization of the properties of DNMT3AC-R882H
In vitromethylation experiments using identical concentra-
tions of DNMT3AC wildtype and R882H showed that the
R882Hmutant has a residual activity of 62%with a 509mer
DNA substrate containing 58 CpG sites, which was ampli-
fied from the CpG island upstream of the human SUHW1
gene (Figure 1A, Supplementary Figures S2 and S3). This
result is comparable to residual activities of R882H ob-
served in other studies (11,20,21). Since it represents a rel-
atively mild reduction in activity, we were curious to study
if other enzymatic properties of DNMT3A were altered by
the mutation. To determine the effect of the mutation on
protein stability, we pre-incubated the wildtype and mutant
enzymes at 22 or 37◦C before measuring the enzymatic ac-
tivities. This caused a reduction of catalytic activity, which
reflects the amount of enzyme denaturation during the pre-
incubation interval. However, we did not observe any dif-
ference in thermal stability between wildtype and R882H in
these experiments (Figure 1B), indicating that the mutation
does not destabilize the enzyme folding. To directly inves-
tigate a potential effect of the R882H mutation on protein
folding, far UV circular dichroism spectra of the purified
DNMT3AC and R882H were determined. The CD spec-
tra were superimposable within the level of noise indicating
a similar folding of wildtype and mutant proteins (Figure
1C). To further examine the potential influence of the mu-
tation on general protein stability, CD-melting experiments
were conducted demonstrating an identical melting temper-
ature of 49.3± 0.4◦C and 49.5± 0.6◦C for DNMT3AC and
R882H (Figure 1D) which confirms the kinetic data shown
in Figure 1B. As the R882Hmutation is located in theDNA
binding interface of DNMT3A, we alsomeasured theDNA
binding constant of R882H by fluorescence depolarization
using a 29mer DNA containing two CpG sites. Our data
show that the R882Hmutant binds the substrate with a KD
of 209±19 nM (Figure 1E), which is only slightly weaker
than the wildtype enzyme (KD = 183±19 nM) measured
under identical conditions with protein preparation that
were purified in parallel (25). Previously it had been shown,
that disruption of the RD interface by an R881A mutation
in murine DNMT3A (the corresponding residue in human
DNMT3A is R885) resulted in a loss of the normal localiza-
tion of EYFP fused DNMT3A at DAPI dense heterochro-
matin in NIH3T3 cells (17,18). To investigate if the R882H
mutation leads to a similar deterioration of the RD inter-
face, we have prepared a murine DNMT3A R878H mutant
(corresponding to the human R882H) fused to EYFP, ex-
pressed the protein in NIH3T3 cells and studied its sub-
nuclear localization by fluorescence microscopy. However,
there was no detectable difference in the sub-nuclear local-
ization between the wildtype DNMT3A and R882H EYFP
fusion proteins (Figure 1F).
Overall, the lack of changes in DNA binding, enzyme
localization and stability indicates that the DNMT3A/3A
RD interface is notmassively deranged by theR882Hmuta-
tion. This conclusion is in agreement with the moderate re-
duction in catalytic activity of the R882H mutant, because
disruption of the RD interface by a R881A mutation in
murine DNMT3AC (corresponding to human R885) com-
pletely inactivated the enzyme (17).
Altered flanking sequence preferences of DNMT3A R882H
Based on the position of the R882H mutation in the DNA
binding interface of DNMT3A, we next investigated if this
mutation influences the specificity of the DNA interaction
of DNMT3A. It has been well documented that DNMT3A
shows pronounced differences in the methylation activity
of CpG sites depending on their flanking sequence (26,35–
37), and CpG sites have been identified which could not be
methylated by DNMT3A at all (26). Moreover, the R882A
mutation had already been shown to alter the relative pref-
erences of themethylation of threeDNAsubstrateswith dif-
ferent flanking sequences (38). We used the purified R882H
mutant protein for our experiments, because it is not possi-
ble to prepare DNMT3AC with a mixed wildtype/R882H
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Figure 2. Flanking sequence analysis of R882H. (A) Bisulfite analysis of the methylation of 56 CpG sites of the 509mer PCR fragment. The figure shows for
each site (1–56), the ratio of the relative methylation levels observed in the wildtype (wt) and R882H samples. In case of zero methylation by the wildtype,
ratios were set to 5.0 (for details see Supplementary Table S1). (B) Distribution of bases at the flanking sequence positions in the 10 sites preferred by
R882H. (C) Distribution of bases at the flanking sequence positions of all sites on the DNA substrate. (D) P-values of enrichment of bases at all flanking
sites in the set of preferred sites (for details see Supplementary Table S2).
RD interface. We conducted methylation kinetics with a
fragment of the 509mer substrate used in the radioactive
methylation assays asDNA substrate, which allows to study
the methylation of 56 CpG sites in different flanking con-
texts, and measured DNA methylation at all CpG sites by
wildtype DNMT3AC and R882H by bisulfite conversion
and sequencing. Wildtype DNMT3A showed strong dif-
ferences in the methylation of different sites in agreement
with previous studies (25,26). In agreement with the gen-
eral reduction of R882H activity, most CpG sites exhibited
lower methylation levels by R882H. However, a compari-
son of the relative methylation levels of different CpG sites
between wildtype and the R882H revealed a strong change
of the flanking sequence preferences of the mutant (Figure
2A). Because of this, some sites showed a much more pro-
nounced reduction of methylation activity than the 38% av-
erage reduction in activity reported above. Even more strik-
ingly, some sites were methylated up to five times faster
by R882H than by the wildtype enzyme. This was mainly
observed at sites which were weakly methylated by wild-
type DNMT3AC, but still methylated with good yields by
R882H.We extracted the –6 to +6 flanks of the 10 sitesmost
preferred by R882H when compared to wildtype and ob-
served a strong overrepresentation of G at the +3 position
(Figure 2B and C). Less pronounced enrichments at other
positions were detected after a statistical analysis compar-
ing the distribution of bases at each flanking position in
the preferred sites with the overall distribution in all sites
(Figure 2D). These results clearly indicate that the flank-
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Figure 3. Design of a preferred R882H substrate. (A) Based on the sequences of the 10 most preferred methylation sites by R882H, a substrate with R882H
optimized flanks was designed together with a reference substrate not containing R882H preferred residues. For each substrate, a hemimethylated version
(hm) and a fully methylated (fm) version was used to allow measurement of the specific methylation activity in the upper DNA strand of the central CpG
site. ‘M’ denotes 5-methyldeoxycytosine, the target C is highlighted in red. (B) Example kinetic data of the methylation of the hm (squares, continuous
lines) and fm (circles, dotted lines) substrates by DNMT3AC (blue) and R882H (orange). (C) Average target site methylation rates of the R882H substrate
and reference substrate by wildtype DNMT3AC andDNMT3AC-R882H. To determine the specific methylation of the central CpG site in the upper DNA
strand, the methylation of the fm substrate is subtracted from the methylation of the hm substrate. Error bars indicate the SEM based on four independent
experiments.
ing sequences of R882H differ substantially from wildtype
DNMT3AC.
Methylation kinetics with designed oligonucleotide sub-
strates
Based on the analysis described in the last section, we de-
signed model substrates containing one central CpG site
with flanks optimized for methylation of the upper DNA
strand by R882H (‘R882H substrate’) and flanks not con-
taining features preferred by R882H (‘reference substrate’)
(Figure 3A). To study only the specific methylation of the
central CpG in the upper strand, we used the designed sub-
strates in hemimethylated form. Moreover, it has been re-
peatedly observed, thatDNMT3Aalsomethylates other cy-
tosine residues in oligonucleotide substrates, which are not
situated in a CpG context (26,27,39,40). This additional ac-
tivity could obscure the comparison of themethylation rates
of the two substrates. Therefore, both designed substrates
were used in an additional control form, where the central
CpG site is methylated in both strands (fully methylated).
Hence, these control substrates could only be methylated at
other cytosine residues. To determine the methylation activ-
ity only for the central CpG in the upper strand, the activ-
ity observed with the fully methylated substrates was sub-
tracted from the activity observed with the corresponding
hemimethylated substrates (Figure 3B).
Methylation experiments of the two substrates in
their hemi- and fully methylated forms with wildtype
DNMT3AC and R882H revealed that methylation of the
R882H substrate by the R882H mutant was 45% faster
than by wildtype DNMT3AC (Figure 3C). In contrast, the
residual activity of R882H on the reference substrate was
<15% when compared to the wildtype enzyme, indicating
that the lack of sequence features preferred by R882H has
led to a very low activity. Strikingly, the overall difference of
the catalytic activities of wildtype and R882H on these two
substrates was ∼10-fold. These results confirm the conclu-
sions of the flanking sequence analysis of methylated sites
by demonstrating that it is possible to design anR882H pre-
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Figure 4. Inhibition of wildtype DNMT3AC and R882H by compound 3 and compound 9. Averages and standard errors from two independent experi-
ments are shown. IC50-values are listed in Table 1.
Table 1. Inhibition of wildtype and R882H mutant by DNMT3A inhibitors (43). IC50 values were derived from 2 independent experiments, in which
inhibitor concentrations were titrated between 1 nM and 400 M. Error margins denote the SD of the fit of the IC50 values. The titration curves are shown
in Figure 4.
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Figure 5. Details of a model of the DNMT3A-DNA complex structure.
The C-backbone of DNMT3A (pdb: 2QRV) is shown in green, R882
is in red. DNA (shown in blue) was modelled into the DNMT3A struc-
ture using the DNA molecule from the M.HhaI-DNA complex structure
(pdb: 1MHT) by superposition of the conserved catalytic methyltrans-
ferase residues of M.HhaI and DNMT3A. The flipped target cytosine is
shown in pink and the +3 base pair in cyan.
ferred and a disfavored substrate on the basis of the flanking
sequence preferences.
Inhibition of DNMT3A R882H by small compounds
Our data indicate that the R882H mutation causes a de-
fined hyperactivity of DNMT3A at a subset of CpG sites.
Hence, an inhibition of the mutated DNMT3A might
be a therapeutic option. Initial studies indeed indicated
that DNMT3A mutant cancer patients respond better to
treatment with nucleosidic hypomethylating agents (41,42).
To investigate the possibility of a direct inhibition of
DNMT3A R882H, we tested two previously validated
DNMT3A inhibitors (43) for their effects on the activity
of the R882H mutant. As shown in Table 1 and Figure
4, one of them (compound 9) showed equal inhibition of
both wildtype and mutant DNMT3AC, while the other
(compound 3) showed a threefold reduced inhibition of the
R882H mutant. Thus, these inhibitors, in particular com-
pound 9, are still active against the mutant DNMT3A.
DISCUSSION
Despite the fact that the R882Hmutation in theDNAbind-
ing interface of DNMT3A is highly prevalent in AML, its
pathogenic mechanism has not been finally clarified at the
molecular level (13). Previous data showed a moderately re-
duced activity of the mutant and a dominant negative effect
of the R882Hmutation (23). Here, we show that the R882H
mutation leads to strong changes in the flanking sequence
preferences of DNMT3A most prominently at the +3 po-
sition but also at other sites. DNMT3A has been shown
previously to exhibit pronounced flanking sequence pref-
erences in the methylation of different CpG sites (26,35–
37), which could be due to flanking sequence effects on the
DNA binding or conformational changes of the DNA dur-
ing complex formation (like DNA bending or unwinding),
but also effects of the flanking sequence on dynamic steps
during catalysis, like target base flipping. Our findings sug-
gests that the R882H exchange directly affects the DNA in-
teraction of DNMT3A. To further explore this point, we
prepared a model of the DNMT3A-DNA complex struc-
ture by using the DNA from the M.HhaI-DNA complex
(44) after superposition of the conserved catalytic methyl-
transferase residues of DNMT3A and M.HhaI (Figure 5).
Strikingly, in this model the R882 side chain is positioned
directly adjacent to the +3 base pair in an ideal position to
contact theDNAbackbone at this site. Thereby,R882 could
probe sequence dependent conformational preferences of
the DNA substrate in a process reminiscent of the classic
indirect readout of DNA sequence by proteins (45,46). This
leads to a complex readout of theDNA sequence dependent
bending and twisting properties of the DNA, mediated by
contacts of the protein to the phosphodiester backbone of
the DNA.
The change in flanking sequence preferences of R882H
reported here uncovers an additional dimension in the ef-
fects of the R882H mutation on the methylation activity of
DNMT3A by showing that the influence of the mutation is
CpG site specific. In addition to the moderate global reduc-
tion of activity, our data show that specific sites are affected
much more strongly and strong hypomethylation as well as
hypermethylation can occur depending on the target site.
Unfortunately, these changes in flanking sequence prefer-
ences observed in vitro cannot be directly compared with
patient data, because in cells DNMT3AR882H can methy-
late the upper or lower DNA strand creating a hemimethy-
lated CpG site. Afterwards, DNMT1 will methylate the
second strand due to its high activity on hemimethylated
CpG sites. Hence, in cellular methylation data sets, one
cannot determine which strand was initially methylated
by DNMT3A. As the flanking preferences are not palin-
dromic, in cellular data all flanking signatures are mixed re-
sulting in very poor statistics.
A gain-of-function effect of the R882H mutation po-
tentially related to hyperactivity at particular sites is in
agreement with its positive correlation with other muta-
tions blocking DNA demethylation, which would enhance
these effects. This refers to the co-occurrence of R882H
with TET2 inactivating mutations in peripheral T-cell lym-
phomas (12,47), which were experimentally shown to co-
operate in the induction of lymphoid malignancies in mice
(47). Along the same line, IDH mutations (which indirectly
reduce the activity of TET enzymes) are also positively cor-
related with DNMT3A R882H in AML and myeloprolif-
erative neoplasm (3,12,48). Finally, some studies indicated
that DNMT3A mutant patients responded better to treat-
ment with hypomethlyating agents (41,42), which could
be explained by the site specific gain-of-function model
of R882H. Future work in hematopoietic stem cells and
AML precursor cells, will be needed to identify the rele-
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vantmethylation sites which are hyper- and hypomethylated
by R882H, connect them with corresponding genes, and
find out, if inhibition of hypermethylation of CpG sites by
DNMT3A-R882H in AML precursor cells may delay the
onset of the disease.
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